CCR 20th Anniversary Commentary: A Genetic Mechanism of Imatinib Resistance in Gastrointestinal Stromal Tumor-Where Are We a Decade Later?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 26240289.
- Also identified by DOI 10.1158/1078-0432.CCR-14-3120 and PMC identifier 4526110.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In the June 1, 2005, issue of Clinical Cancer Research, Antonescu and colleagues defined second-site KIT mutations in gastrointestinal stromal tumor (GIST) as the leading mechanism of acquired resistance to imatinib. Secondary mutations were detectable mainly in KIT exon 11 mutant GISTs after prolonged initial clinical responses. These findings played a critical role in designing the next generation of tyrosine kinase inhibitors.
Medical subject headings
- Drug Resistance, Neoplasm
- Gastrointestinal Stromal Tumors
- Mutation
- Piperazines
- Pyrimidines